1065 EAST HILLSDALE BLVD., SUITE 100, FOSTER CITY, CA
Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist in Obesity
Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
Shareholder votes
Annual Report to Security Holders
Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
Appoints Andrew Gengos as Chief Financial Officer
Changes in Board, Management or Compensation, Reg. FD
Changes in Board, Management or Compensation
Q2
Q1
FY 2024
FY 2023
Q3
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership